[
    [
        {
            "time": "2020-Q3",
            "original_text": "贝达药业(300558)2020三季报点评：埃克替尼稳健增长 业绩符合预期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "三季报",
                    "稳健增长",
                    "业绩符合预期"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)2020三季报点评：埃克替尼稳健增长 业绩符合预期",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "贝达药业(300558)：埃克替尼Q3恢复增长 静待新品获批",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "Q3",
                    "恢复增长",
                    "新品获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：埃克替尼Q3恢复增长 静待新品获批",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "贝达药业(300558)：现金流稳步提升 创新品种将迎来密集收获期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "现金流",
                    "稳步提升",
                    "创新品种",
                    "密集收获期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：现金流稳步提升 创新品种将迎来密集收获期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]